Researchers discover link between expression of GATM and pain associated with statins

August 29, 2013 by Bob Yirka report

(Medical Xpress)—A large team with members from several research institutions across the U.S. has found a possible link between the expression of the gene for glycine amidinotransferase (GATM) and pain experienced by patients who take statins to help lower their cholesterol levels. In their paper published in the journal Nature, the team describes their findings and what it might mean for patients in the near future.

People across the world are prescribed statins to help lower levels of cholesterol in their blood—the hope is that such a reduction will reduce the risk of heart attack and stroke. Statins generally do their work on the liver, helping to prevent cholesterol from being released into the bloodstream. In many instances, however, the use of statins in patients has led to muscle pain (known as ) and an increased risk of developing Type II diabetes. In this new effort the researchers sought to learn if there might be a genetic difference between patients who experience pain when using statins and those who do not.

Rather than looking for in the livers of patients, the researchers used lymphoblastoid cell lines that had been obtained from a patients prescribed simvastatin (Zocor) as part of trial testing—lymphoblastoids are a type of immune cell that can serve as a proxy for .

The researchers treated the cells they had obtained with the statin and then searched for changes to expressions by genes that were impacted. After much work, the team began to focus on GATM—it's involved in synthesizing creatine which is known to serve as food for muscles, particularly those that work with the skeletal system. Once GATM had been identified as a possible source, the researchers looked at of statin prescribed patients to see if they could find a link. Sure enough, those that had experienced pain also had different levels of creatine in their muscles than those that did not. Subsequent tests revealed that if GATM levels were artificially reduced, liver cell response was changed, though the researchers still aren't clear as to whether that would lead to less pain in patients.

The researchers note that while their research thus far has found a link between GATM levels and muscle pain, much more work will need to be done to determine if a way can be found to use that knowledge to reduce the painful side effects of statins in some patients.

Explore further: Cholesterol medicine affects energy production in muscles

More information: A statin-dependent QTL for GATM expression is associated with statin-induced myopathy, Nature (2013) DOI: 10.1038/nature12508

Statins are prescribed widely to lower plasma low-density lipoprotein (LDL) concentrations and cardiovascular disease risk and have been shown to have beneficial effects in a broad range of patients. However, statins are associated with an increased risk, albeit small, of clinical myopathy and type 2 diabetes. Despite evidence for substantial genetic influence on LDL concentrations, pharmacogenomic trials have failed to identify genetic variations with large effects on either statin efficacy or toxicity, and have produced little information regarding mechanisms that modulate statin response. Here we identify a downstream target of statin treatment by screening for the effects of in vitro statin exposure on genetic associations with gene expression levels in lymphoblastoid cell lines derived from 480 participants of a clinical trial of simvastatin treatment7. This analysis identified six expression quantitative trait loci (eQTLs) that interacted with simvastatin exposure, including rs9806699, a cis-eQTL for the gene glycine amidinotransferase (GATM) that encodes the rate-limiting enzyme in creatine synthesis. We found this locus to be associated with incidence of statin-induced myotoxicity in two separate populations (meta-analysis odds ratio = 0.60). Furthermore, we found that GATM knockdown in hepatocyte-derived cell lines attenuated transcriptional response to sterol depletion, demonstrating that GATM may act as a functional link between statin-mediated lowering of cholesterol and susceptibility to statin-induced myopathy.

Related Stories

Cholesterol medicine affects energy production in muscles

January 3, 2013

Up to 75 per cent of patients who take statins to treat elevated cholesterol levels may suffer from muscle pain. Scientists at the Center for Healthy Aging at the University of Copenhagen have now identified a possible mechanism ...

Statin use linked to few side effects

July 9, 2013

the popular class of cholesterol-lowering drugs used widely to prevent recurrent heart disease or stroke as well as risk for having a first cardiac or stroke event—appear to cause few side effects, according to new research ...

Recommended for you

Macrophages shown to be essential to a healthy heart rhythm

April 20, 2017

A Massachusetts General Hospital (MGH)-led research team has identified a surprising new role for macrophages, the white blood cells primarily known for removing pathogens, cellular debris and other unwanted materials. In ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.